The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

• Published in: Familial cancer Vol. 16; no. 3; pp. 339 - 349
• Main Authors: Song, Jun-Long, Chen, Chuang, Yuan, Jing-Ping, Sun, Sheng-Rong
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.07.2017; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Cancer Research; Epidemiology; Family medical history; Female; Genetic Predisposition to Disease - genetics; Health risk assessment; Human Genetics; Humans; Mastectomy; Meta-analysis; Ovarian cancer; Ovarian Neoplasms - genetics; Population studies; Prognosis; Review; Surgery; Survival; Survival Analysis; Systemic review; Breast cancer; Prognosis; Family history
• ISSN: 1389-9600; 1573-7292
• DOI: 10.1007/s10689-017-9969-x

Whether a positive family history of breast cancer or ovarian cancer (FHBOC) would affect the prognosis of breast cancer is still up for debate and further study. This meta-analysis was performed to clarify this issue. We reviewed two databases (PubMed and CNKI) for research articles published at any time from the inception of these databases to April 1, 2016 for articles detecting the impact of FHBOC on the prognosis of breast cancer. A meta-analysis was conducted to generated combined hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and breast cancer-specific survival (BCSS). Eighteen studies were included in our qualitative analysis, with 15 studies ultimately part of the quantitative analysis. The pooled results demonstrated that a positive FHBOC was associated with better OS (0.89, 95% CI 0.83–0.95) and BCSS (0.90, 95% CI 0.82–0.99). In subgroup analyses, several subgroups (maximally adjusted studies, population based studies, high quality studies, family history of breast cancer, studies from Europe, studies from Asia, 1 affected relative, or tumor size > 2 cm), a positive first-degree FHBOC was associated with better prognosis of breast cancer. Notably, for those patients who underwent breast-conserving surgery, first-degree FHBOC was not a risk factor for OS (HR 1.08, 95% CI 0.53–2.21). Our meta-analysis demonstrated that a first-degree FHBOC was associated with better OS and BCSS in patients with breast cancer. These findings support that clinical management should not differ between women with and without FHBOC.